Century Therapeutics (IPSC) R&D In Process (2022)
Century Therapeutics (IPSC) has disclosed R&D In Process for 1 consecutive years, with $10.0 million as the latest value for Q1 2022.
- On a quarterly basis, R&D In Process changed N/A to $10.0 million in Q1 2022 year-over-year; TTM through Dec 2022 was $10.0 million, a N/A change, with the full-year FY2022 number at $10.0 million, changed N/A from a year prior.
- R&D In Process was $10.0 million for Q1 2022 at Century Therapeutics.
- In the past five years, R&D In Process ranged from a high of $10.0 million in Q1 2022 to a low of $10.0 million in Q1 2022.